Literature DB >> 8420323

Leiomyosarcomas: clinical presentation.

L B Schwartz1, M P Diamond, P E Schwartz.   

Abstract

OBJECTIVE: The ability to preoperatively distinguish benign from malignant myomas is increasingly important because of the availability of more conservative approaches to management of patients with benign uterine enlargement who wish to preserve fertility. Such therapies include observation, medical treatment with gonadotropin-releasing hormone analogs, and hysteroscopic resection of submucosal leiomyomas. In view of these options, this study was undertaken to identify characteristic features of leiomyosarcomas that may preoperatively distinguish benign from malignant myomas. STUDY
DESIGN: The 10-year experience with 21 patients with uterine leiomyosarcomas at Yale-New Haven Hospital was retrospectively reviewed.
RESULTS: Leiomyosarcomas were both broad-based and pedunculated and had no preferential uterine location. In 95% of the uterine specimens the leiomyosarcoma was either the largest or the only mass. The leiomyosarcoma was limited to one mass in all patients but one.
CONCLUSION: We recommend that the largest myoma be monitored most closely during conservative management of a uterus containing leiomyomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420323     DOI: 10.1016/s0002-9378(12)90910-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  [Imaging before and after uterine artery embolization].

Authors:  T J Kröncke
Journal:  Radiologe       Date:  2008-07       Impact factor: 0.635

Review 2.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

3.  Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Authors:  Kari J Brewer Savannah; Elizabeth G Demicco; Kristelle Lusby; Markus Ph Ghadimi; Roman Belousov; Eric Young; Yiqun Zhang; Kai-Lieh Huang; Alexander J Lazar; Kelly K Hunt; Raphael E Pollock; Chad J Creighton; Matthew L Anderson; Dina Lev
Journal:  Clin Cancer Res       Date:  2012-07-20       Impact factor: 12.531

4.  Involvement of oxidatively damaged DNA and repair in cancer development and aging.

Authors:  Barbara Tudek; Alicja Winczura; Justyna Janik; Agnieszka Siomek; Marek Foksinski; Ryszard Oliński
Journal:  Am J Transl Res       Date:  2010-05-15       Impact factor: 4.060

5.  [Relapsing uterine leiomyosarcoma: report of a case].

Authors:  Youssef Benabdejlil; Mohammed Elmarjany; Abdellah Babahabib; Mehdi Elhassani; Hafsa Chahdi; Jaouad Kouach; Driss Rahali Moussaoui; Mohammed Dehayni
Journal:  Pan Afr Med J       Date:  2014-09-24

6.  Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma.

Authors:  Jasmine H Francis; Ruth A Kleinerman; Johanna M Seddon; David H Abramson
Journal:  Gynecol Oncol       Date:  2011-10-23       Impact factor: 5.482

7.  [Role of magnetic resonance imaging (MRI) in establishing the indication for, planning, and following up uterine artery embolization (UAE) for treating symptomatic leiomyomas of the uterus].

Authors:  T J Kröncke; B Hamm
Journal:  Radiologe       Date:  2003-08       Impact factor: 0.635

Review 8.  Options on fibroid morcellation: a literature review.

Authors:  Hans Brölmann; Vasilios Tanos; Grigoris Grimbizis; Thomas Ind; Kevin Philips; Thierry van den Bosch; Samir Sawalhe; Lukas van den Haak; Frank-Willem Jansen; Johanna Pijnenborg; Florin-Andrei Taran; Sara Brucker; Arnaud Wattiez; Rudi Campo; Peter O'Donovan; Rudy Leon de Wilde
Journal:  Gynecol Surg       Date:  2015-02-07

9.  Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.

Authors:  Jeong Yeol Park; Jeong Won Lee; Hyun Ju Lee; Jong Jin Lee; Seung Hwan Moon; Seo Young Kang; Gi Jeong Cheon; Hyun Hoon Chung
Journal:  J Gynecol Oncol       Date:  2017-02-02       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.